AMARIN CORPORATION PLC - AMERICAN DEPOSITARY SHARE

Amarin to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021

16 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Amarin Reports Subgroup Data from REDUCE-IT® Highlighting Benefits of VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Prior Peripheral Artery Disease (PAD) Presented in Rapid Fire Oral Session Presentation at the American Heart Association Scientific Sessions 2021

15 Nov 2021 16:30:00 By Nasdaq GlobeNewswire

Amarin to Present at Two Upcoming Investor Conferences

11 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Latest Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) to be Presented at American Heart Association Scientific Sessions 2021

08 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Amarin Reports Third Quarter 2021 Financial Results and Provides Business Update

03 Nov 2021 06:00:00 By Nasdaq GlobeNewswire

Amarin to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

20 Oct 2021 07:05:00 By Nasdaq GlobeNewswire

Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S.

22 Sep 2021 09:15:00 By Nasdaq GlobeNewswire

Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany

13 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Amarin to Participate in September Investment Conferences

13 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at ESC Congress 2021, Organized by the European Society of Cardiology

31 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Society of Cardiology

23 Aug 2021 03:15:00 By Nasdaq GlobeNewswire

Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021, Organized by the European Society of Cardiology

16 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

Amarin Reports Second Quarter and Six Month 2021 Financial Results and Provides Business Update

05 Aug 2021 06:00:01 By Nasdaq GlobeNewswire

Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021

15 Jul 2021 06:35:00 By Nasdaq GlobeNewswire

Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique Form of Eicosapentaenoic Acid (EPA) Presented at the European Atherosclerosis Society (EAS) Congress 2021

02 Jun 2021 16:30:00 By Nasdaq GlobeNewswire

Amarin to Present at Two Investor Conferences in June 2021

18 May 2021 06:05:00 By Nasdaq GlobeNewswire

Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the American College of Cardiology’s 70th Annual Scientific Session

17 May 2021 16:05:02 By Nasdaq GlobeNewswire

REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented at the American College of Cardiology’s 70th Annual Scientific Session

15 May 2021 08:00:00 By Nasdaq GlobeNewswire

Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology’s 70th Annual Scientific Session

04 May 2021 07:00:01 By Nasdaq GlobeNewswire